Ashland — Nov 4, 2025 release

Fiscal 2026 strategic priority targets • Execute : achieve approximately $30 million in cost savings under the $90 million program. • Globalize : generate $20 million in incremental sales by scaling high quality business lines, biofunctional actives, microbial protection, injectables and tablet coatings, across regions and customers. • Innovate : $15 million in incremental innovation driven sales will come from commercializing new technologies and scaling recent launches.   Other key factors included in fiscal 2026 guidance • Accrual of performance-based compensation at target levels and merit increases totaling approximately $20 million • Calvert City production unit: As previously disclosed, the primary impact is related to repairs and lower operational efficiency across its integrated plant network, which is expected to reduce adjusted EBITDA by roughly $10 million • Incremental investments in research and development to advance disruptive platform opportunities of about $4 million   “Our teams executed well in a challenging environment and remained aligned to our strategy throughout fiscal 2025. Our fiscal 2026 guidance reflects a prudent view of current market conditions, including the previously shared shift in timing for benefits from our manufacturing optimization program. While operational actions are largely complete, financial delivery will be more weighted to future periods. Importantly, our planning scenarios reflect a return to growth, signaling a constructive shift in trajectory and renewed momentum across our businesse